Tumor-Agnostic Biomarkers and Targeted Treatment of Advanced Colorectal Cancer

Source: Biomarkers in Gastrointestinal Cancer: Expert Perspectives and Guidance for Individualized Treatment
Download Slideset
Download this slideset for expert perspectives on best practices in testing for tumor-agnostic and CRC-specific biomarkers—including MSI/MMR, TMB, NTRK fusions, BRAF/RAS mutations, and HER2 amplifications—and use of related targeted therapeutics.
John L. Marshall, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 1.01 MB
Released: June 3, 2022

Acknowledgements

Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
Bayer HealthCare Pharmaceuticals Inc.
Daiichi Sankyo, Inc.
Seagen Inc.
Turning Point Therapeutics, Inc.

Related Content

Updated data from the CheckMate 648 study of first-line nivolumab + either chemotherapy or ipilimumab for esophageal SCC, presented at ASCO GI 2023 and reported by Clinical Care Options (CCO)

Released: February 2, 2023

Phase II trial evaluating pemigatinib for previously treated mCRC with FGF/FGFR alterations, presented at ASCO GI 2023 and reported by Clinical Care Options (CCO)

Released: January 30, 2023

Updated data from the CheckMate 649 study of nivolumab + chemotherapy for advanced gastric/GEJ cancer and esophageal adenocarcinoma, presented at ASCO GI 2023 and reported by Clinical Care Options (CCO)

Released: January 30, 2023

MOUNTAINEER concordance analysis between breast and gastric algorithms for HER2 testing in mCRC, presented at ASCO GI 2023 and reported by Clinical Care Options (CCO)

Released: January 30, 2023

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings